| DC73612 |
Glutipyran |
Glutipyran is a small-molecule glucose transporter inhibitor, inhibits glycolytic activity and cell growth in human pancreatic cancer cells. |
|
| DC73613 |
(R)-AS-1 |
(R)-AS-1 is an orally bioavailable, selective positive allosteric modulator (PAM) of the glutamate transporter EAAT2 with EC50 of 11 nM and Emax of 251%, shows potent antiseizure activity in vivo. |
|
| DC73614 |
GT951 |
GT951 (GT-951) is a potent, selective activator (positive allosteric modulator) of EAAT2 with EC50 of 0.8 nM in vitro glutamate uptake assays in COS cells overexpressing EAAT2. |
|
| DC73615 |
GTS467 |
GTS476 (GTS-476) is a potent, selective, orally active activator of EAAT2 with EC50 of 35.1 nM in vitro glutamate uptake assays in COS cells overexpressing EAAT2. |
|
| DC73616 |
GTS511 |
GTS511 (GTS-511) is a potent, selective, brain-permeable activator of EAAT2 with EC50 of 3.8 nM in vitro glutamate uptake assays in COS cells overexpressing EAAT2. |
|
| DC73617 |
NV-6297
Featured
|
NV-6297 (NV6297) is a potent, selective mTORC1 pathway signaling inhibitor without inhibition on mTORC2, inhibits S6K1 phosphorylation (pS6K1 T389) in MCF7 cells with IC50 of 120 nM, directly and selectively targets GLUT-1. |
|
| DC73618 |
NUCC-0200590 |
NUCC-0200590 is a small-molecule inhibitor of the TRIP8b-HCN interaction with IC50 of 7.0 uM in AlphaScreen assays, effectively disrupts the TRIP8b-HCN interaction in vitro and in vivo. |
|
| DC73619 |
Org 34167
Featured
|
Org 34167 HCl salt is a broad-spectrum inhibitor of HCN channels with IC50 of 23.4, 8.2 and 9.2 uM for HCN1, HCN2 and HCN4 channels, respectively, slowing activation and causing a hyperpolarising shift in voltage-dependence of activation. |
|
| DC73620 |
RO-275 |
RO-275 is a potent, selective HCN1 ion channel inhibitor with IC50 of 46 nM, displays 311/100/302-fold selectivity over HCN2/HCN3/HCN4. |
|
| DC73621 |
(R)-OF-NB1 |
(R)-OF-NB1 is a small molecule splice variant GluN2B-selective NMDAR antagonist with IC50 of 675 nM and 97 nM for F-NB1 for splice variant containing exon 5 and GluN1-1a in X. laevis oocytes. |
|
| DC73622 |
(S)-(-)-DQP-997-74 |
(S)-(-)-DQP-997-74 is a potent, selective GluN2C- and GluN2D-containing NMDARs negative allosteric modulator with IC50 of 69 and 35 nM, respectively, exhibits >100- and >300-fold over GluN2A- and GluN2B-containing receptors. |
|
| DC73623 |
DQP-997-74 |
DQP-997-74 is a potent, selective GluN2C- and GluN2D-containing NMDARs negative allosteric modulator with IC50 of 0.35 and 0.13 uM, respectively, exhibits >100-fold over GluN2A- and GluN2B-containing receptors. |
|
| DC73624 |
FP802
Featured
|
FP802 is a novel small molecule with significant neuroprotective properties, specifically designed to target and disrupt the TwinF interface within the NMDAR/TRPM4 death signaling complex. This unique mechanism allows FP802 to selectively eliminate extrasynaptic NMDAR (eNMDAR)-mediated toxicity, which is implicated in various neurodegenerative diseases, while preserving the essential physiological functions of synaptic NMDARs. This selectivity makes FP802 a promising therapeutic candidate for conditions involving excitotoxicity and neuronal cell death. |
|
| DC73625 |
GluN2A PAM (R)-9 |
GluN2A PAM (R)-9 is a potent, brain penetrant, GluN2A-selective positive allosteric modulator with EC50 of 0.51 uM, Emax 350%. |
|
| DC73626 |
Org 26576 |
Org 26576 (MK 8777. |
|
| DC73627 |
PTC-174 |
PTC-174 is a selective, positive allosteric modulator of NMDA receptors containing GluN2C or GluN2D subunits with EC50 of 4.1 uM (GluN1/2C) and 5.7 uM (GluN1/2D). |
|
| DC73628 |
UBP1700 |
UBP1700 is a subtype-selective competitive antagonist of GluN2C/2D-containing NMDA receptors with Ki of 7-9 nM, 50-fold selectivity over GluN2A and GluN2B. |
|
| DC73629 |
UBP791 |
UBP791 is a subtype-selective competitive antagonist of GluN2C/2D-containing NMDA receptors with Ki of 80-90 nM, 50-fold selectivity over GluN2A and GluN2B. |
|
| DC73630 |
UBP792 |
UBP792 is a novel negative allosteric modulator (antagonist) of NMDA receptors, displays partial subtype-selectivity by having a varied maximal inhibition of GluN2A-, GluN2B-, GluN2C-, and GluN2D-containing receptors (52%, 70%, 87%, 89%, respectively) wit |
|
| DC73631 |
ZCAN155 |
ZCAN155 is a small molecule that prevents AMPA-mediated excitotoxicity (IC50=35 nM) by targeting an allosteric binding site of AMPA glutamate receptor 2 (GluA2), restores neurological function and myelination. |
|
| DC73632 |
ZCAN262 |
ZCAN262 is a small molecule that prevents AMPA-mediated excitotoxicity (IC50=8.5 nM) by targeting an allosteric binding site of AMPA glutamate receptor 2 (GluA2). |
|
| DC73633 |
(S)-CE-123 |
(S)-CE-123 is a specific small molecule dopamine transporter (DAT) inhibitor, improves memory acquisition and memory retrieval. |
|
| DC73634 |
CDTP-32476 |
CDTP-32476 is a potent slow-onset dopamine reuptake blocker with an affinity of 8.6 nM, CDTP-32476 is moderately selective (14-fold) versus NE reuptake blockade with little effect on the SERT. |
|
| DC73635 |
D-578 |
D-578 is a potent, orally active triple monoamine reuptake inhibitor with Ki values of 16.2. 16.2, 3.23 nM, and 29.6, 20.6, 6.10 nM for the rat brain and cloned human dopamine, serotonin and norepinephrine transporters, respectively. |
|
| DC73636 |
FFN200 |
FFN200 is a vesicular monoamine transporter 2 (VMAT2) substrate, and the first probe to selectively trace monoamine exocytosis in both neuronal cell culture and brain tissue. |
|
| DC73637 |
GZ-11608 |
GZ-11608 is a potent and selective vesicular monoamine transporter-2 (VMAT2) inhibitor with Ki of 25 nM, GZ-11608 (EC50=620 nM) released vesicular dopamine 25-fold less potently than it inhibited VMAT2 dopamine uptake. |
|
| DC73638 |
GZ-794A |
GZ-794A is a potent, selective inhibitor of vesicular monoamine transporter-2 (VMAT2) with Ki of 30 nM, inhibits methamphetamine-evoked endogenous dopamine release with IC50 of 0.4 uM, shows potential for treatment for methamphetamine abuse. |
|
| DC73639 |
JJC8-016 |
JJC8-016 is a potent, Modafinil-derived dopamine transporter (DAT) ligand with Ki of 116 nM, attenuates compulsive-like methamphetamine self-administration in rats. |
|
| DC73640 |
JJC8-088 |
JJC8-088 is a potent, Modafinil-derived dopamine transporter (DAT) ligand with Ki of 2.53 nM. |
|
| DC73641 |
JJC8-091 |
JJC8-091 is a potent, Modafinil-derived dopamine transporter (DAT) ligand with Ki of 16.7 nM, attenuates compulsive-like methamphetamine self-administration in rats. |
|
